Controversy of hormone treatment and cardiovascular function: Need for strengthened collaborations between preclinical and clinical scientists

Virginia M Miller, Lynne T. Shuster, Sharonne N. Hayes

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Over the last five years, there have been several major randomized clinical trials assessing the use of hormone therapy as an adjunct treatment for primary and secondary prevention of cardiovascular disease. Results of these trials have called into question existing dogma from epidemiological and basic science studies that estrogen provides protection against development of cardiovascular disease. When studies are evaluated for design, type and duration of hormone treatment, and outcomes, directions for future research become apparent. Improved hormone formulations and selective estrogen receptor modulators that help to maintain vascular function and limit progression of cardiovascular occlusive disease need to be developed. This will depend upon improved understanding of: (i) the distribution and regulation of estrogen receptors in vascular tissue, (ii) genomic interactions of estrogens and progestins, (iii) association of the estrogen receptor and other genetic polymorphisms with particular vascular functions, and (iv) better definition of timing and dosing for therapeutic intervention. The mechanisms of interactions between coagulation proteins, inflammatory cytokines, platelets and the vessel wall should be defined so that the thrombotic risk for an individual woman can be identified and reduced, and progression of chronic disease processes associated with loss of ovarian hormones can be slowed.

Original languageEnglish (US)
Pages (from-to)1220-1232
Number of pages13
JournalCurrent Opinion in Investigational Drugs
Volume4
Issue number10
StatePublished - Oct 2003

Fingerprint

Hormones
Blood Vessels
Cardiovascular Diseases
Estrogen Receptors
Estrogens
Selective Estrogen Receptor Modulators
Genetic Polymorphisms
Progestins
Primary Prevention
Therapeutics
Secondary Prevention
Chronic Disease
Blood Platelets
Randomized Controlled Trials
Cytokines
Proteins
Direction compound

Keywords

  • 17β-estradiol
  • Aromatase inhibitors
  • Conjugated equine estrogen
  • Selective estrogen receptor modulators
  • Venous thrombosis
  • Women's Health Initiative

ASJC Scopus subject areas

  • Pharmacology

Cite this

Controversy of hormone treatment and cardiovascular function : Need for strengthened collaborations between preclinical and clinical scientists. / Miller, Virginia M; Shuster, Lynne T.; Hayes, Sharonne N.

In: Current Opinion in Investigational Drugs, Vol. 4, No. 10, 10.2003, p. 1220-1232.

Research output: Contribution to journalArticle

@article{9f8dcdcf7f0144548f5c8a798af3790d,
title = "Controversy of hormone treatment and cardiovascular function: Need for strengthened collaborations between preclinical and clinical scientists",
abstract = "Over the last five years, there have been several major randomized clinical trials assessing the use of hormone therapy as an adjunct treatment for primary and secondary prevention of cardiovascular disease. Results of these trials have called into question existing dogma from epidemiological and basic science studies that estrogen provides protection against development of cardiovascular disease. When studies are evaluated for design, type and duration of hormone treatment, and outcomes, directions for future research become apparent. Improved hormone formulations and selective estrogen receptor modulators that help to maintain vascular function and limit progression of cardiovascular occlusive disease need to be developed. This will depend upon improved understanding of: (i) the distribution and regulation of estrogen receptors in vascular tissue, (ii) genomic interactions of estrogens and progestins, (iii) association of the estrogen receptor and other genetic polymorphisms with particular vascular functions, and (iv) better definition of timing and dosing for therapeutic intervention. The mechanisms of interactions between coagulation proteins, inflammatory cytokines, platelets and the vessel wall should be defined so that the thrombotic risk for an individual woman can be identified and reduced, and progression of chronic disease processes associated with loss of ovarian hormones can be slowed.",
keywords = "17β-estradiol, Aromatase inhibitors, Conjugated equine estrogen, Selective estrogen receptor modulators, Venous thrombosis, Women's Health Initiative",
author = "Miller, {Virginia M} and Shuster, {Lynne T.} and Hayes, {Sharonne N.}",
year = "2003",
month = "10",
language = "English (US)",
volume = "4",
pages = "1220--1232",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Controversy of hormone treatment and cardiovascular function

T2 - Need for strengthened collaborations between preclinical and clinical scientists

AU - Miller, Virginia M

AU - Shuster, Lynne T.

AU - Hayes, Sharonne N.

PY - 2003/10

Y1 - 2003/10

N2 - Over the last five years, there have been several major randomized clinical trials assessing the use of hormone therapy as an adjunct treatment for primary and secondary prevention of cardiovascular disease. Results of these trials have called into question existing dogma from epidemiological and basic science studies that estrogen provides protection against development of cardiovascular disease. When studies are evaluated for design, type and duration of hormone treatment, and outcomes, directions for future research become apparent. Improved hormone formulations and selective estrogen receptor modulators that help to maintain vascular function and limit progression of cardiovascular occlusive disease need to be developed. This will depend upon improved understanding of: (i) the distribution and regulation of estrogen receptors in vascular tissue, (ii) genomic interactions of estrogens and progestins, (iii) association of the estrogen receptor and other genetic polymorphisms with particular vascular functions, and (iv) better definition of timing and dosing for therapeutic intervention. The mechanisms of interactions between coagulation proteins, inflammatory cytokines, platelets and the vessel wall should be defined so that the thrombotic risk for an individual woman can be identified and reduced, and progression of chronic disease processes associated with loss of ovarian hormones can be slowed.

AB - Over the last five years, there have been several major randomized clinical trials assessing the use of hormone therapy as an adjunct treatment for primary and secondary prevention of cardiovascular disease. Results of these trials have called into question existing dogma from epidemiological and basic science studies that estrogen provides protection against development of cardiovascular disease. When studies are evaluated for design, type and duration of hormone treatment, and outcomes, directions for future research become apparent. Improved hormone formulations and selective estrogen receptor modulators that help to maintain vascular function and limit progression of cardiovascular occlusive disease need to be developed. This will depend upon improved understanding of: (i) the distribution and regulation of estrogen receptors in vascular tissue, (ii) genomic interactions of estrogens and progestins, (iii) association of the estrogen receptor and other genetic polymorphisms with particular vascular functions, and (iv) better definition of timing and dosing for therapeutic intervention. The mechanisms of interactions between coagulation proteins, inflammatory cytokines, platelets and the vessel wall should be defined so that the thrombotic risk for an individual woman can be identified and reduced, and progression of chronic disease processes associated with loss of ovarian hormones can be slowed.

KW - 17β-estradiol

KW - Aromatase inhibitors

KW - Conjugated equine estrogen

KW - Selective estrogen receptor modulators

KW - Venous thrombosis

KW - Women's Health Initiative

UR - http://www.scopus.com/inward/record.url?scp=0242574365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242574365&partnerID=8YFLogxK

M3 - Article

C2 - 14649215

AN - SCOPUS:0242574365

VL - 4

SP - 1220

EP - 1232

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 10

ER -